| P2093 | author name string | Peter Reichardt | |
| | Matthias Egger | |
| | Thomas Seufferlein | |
| | Lothar Müller | |
| | Frank Kullmann | |
| | Henning Eschenburg | |
| | Alexander Schmittel | |
| | Thomas Zander | |
| | Andreas Block | |
| | Claudia Pauligk | |
| | Thorsten Oliver Goetze | |
| | Salah-Eddin Al-Batran | |
| | Mathias Kleiß | |
| | Alexander Reichart | |
| | Claus Bolling | |
| | Harald Schmalenberg | |
| | Udo Lindig | |
| P2860 | cites work | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Q29620155 |
| | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 |
| | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial | Q29620917 |
| | Capecitabine and oxaliplatin for advanced esophagogastric cancer. | Q33313072 |
| | Single-Agent Irinotecan as Second-Line Treatment for Advanced Gastric Cancer | Q33357475 |
| | Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group | Q34572233 |
| | Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie | Q34594956 |
| | Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. | Q35045144 |
| | Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. | Q38420500 |
| | Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. | Q39165788 |
| | Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLO | Q40487371 |
| | Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy | Q40538283 |
| | Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). | Q42608504 |
| | Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). | Q44687159 |
| | Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400 | Q44754243 |
| | Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie | Q46694609 |
| | Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis | Q46796721 |
| | Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial | Q48117450 |
| | Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. | Q53384216 |
| | Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. | Q53604465 |
| | A Phase I study of cabazitaxel in patients with advanced gastric cancer who have failed prior chemotherapy (GASTANA). | Q53673558 |
| | [German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. | Q55054165 |
| | A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer | Q73269105 |
| | A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy | Q80371789 |
| | Gastric cancer | Q84276928 |
| P921 | main subject | metastatic adenocarcinoma | Q18975291 |
| P577 | publication date | 2017-12-28 | |
| P1433 | published in | Journal of Cancer Research and Clinical Oncology | Q2081599 |
| P1476 | title | CabaGast: multicentre, Phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the esophagogastric junction and stomach | |